Potential Drug Interactions in Hospitalized Hematologic Cancer Patients: New Update with New Chemotherapy Regimens

Abstract

Gaucher's disease (GD) is one of the most common lysosomal diseases in humans. It results from β-glucosidase deficiency and leads to necrosis, especially in macrophages with the accumulation of glucosylceramidase in cells. Most of the deleterious effects of the disease are seen in the liver, spleen, and bone marrow. The aim of this study was to compare the efficacy of Imiglucerase with Eliglustat in treating patients with GD. PubMed/Medline, Cochrane Library, Scopus, Web of Science, Embase, and Google Scholar were searched from inception to August, 2018. Predefined inclusion criteria for included studies were based on search methodology and are as follows: All randomized, quasi-randomized controlled, and cohort studies about patients with GD Type 1 that Imiglucerase was compared with Eliglustat were included. Two authors independently choose the papers based on the inclusion criteria. From 2979 recognized studies, three studies including two randomized clinical trials and one cohort study were recognized to meet the inclusion criteria. The primary outcomes were hemoglobin level, platelets count, liver, and spleen size, and the secondary outcomes were the immunological side effects of the medicines and bone complications. The results showed that there is no meaningful difference between the two medicines in terms of increasing blood hemoglobin, platelets count, and reducing the liver and spleen size. The findings of this review showed that both medicines are effective in the treatment of GD Type 1 and there is no statistically significant difference between their efficacies.

Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease

“…Eliglustat and Miglustat are GCS inhibitors that have been approved for the treatment of GD1 6 . These marketed GCS inhibitors are generally well tolerated, safe, and effective at treating GSL storage diseases by reducing the synthesis of the GSLs that accumulate in these diseases 18,19 . This therapeutic approach is referred to as substrate reduction therapy (SRT) because it reduces the synthesis of the molecules that directly contribute to these different storage diseases.…”

“…6 These marketed GCS inhibitors are generally well tolerated, safe, and effective at treating GSL storage diseases by reducing the synthesis of the GSLs that accumulate in these diseases. 18,19 This therapeutic approach is referred to as substrate reduction therapy (SRT) because it reduces the synthesis of the molecules that directly contribute to these different storage diseases. The GCS inhibitors venglustat and lucerastat are currently in clinical development for GSL storage disorders.…”

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy

“…In view of an apparent inferior efficacy and a more problematic safety profile, including cardiac adverse events (AEs) in at least 5% of the patients who participated in the clinical trials of eliglustat [ 3 , 4 ], we among other investigators have challenged the justification of eliglustat label indicating first-line therapy and suggested to use it as a second-line therapeutic option for patients with GD1 who are unwilling or unable to receive ERT [ 4 , 5 ]. This approach has been criticized by a greater number of investigators who consider eliglustat to be equal to ERT [ 6 , 7 ].…”